ATE418550T1 - 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen - Google Patents
8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungenInfo
- Publication number
- ATE418550T1 ATE418550T1 AT04764687T AT04764687T ATE418550T1 AT E418550 T1 ATE418550 T1 AT E418550T1 AT 04764687 T AT04764687 T AT 04764687T AT 04764687 T AT04764687 T AT 04764687T AT E418550 T1 ATE418550 T1 AT E418550T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- piperazinyl
- quinoline derivatives
- cns diseases
- cns
- Prior art date
Links
- DCUZDOXGNVJQQL-UHFFFAOYSA-N 8-piperazin-1-ylquinoline Chemical class C1CNCCN1C1=CC=CC2=CC=CN=C12 DCUZDOXGNVJQQL-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Psychiatry (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0320320.5A GB0320320D0 (en) | 2003-08-29 | 2003-08-29 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE418550T1 true ATE418550T1 (de) | 2009-01-15 |
Family
ID=28686602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04764687T ATE418550T1 (de) | 2003-08-29 | 2004-08-26 | 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080275040A1 (de) |
| EP (1) | EP1660483B1 (de) |
| JP (1) | JP2007504114A (de) |
| AT (1) | ATE418550T1 (de) |
| DE (1) | DE602004018658D1 (de) |
| GB (1) | GB0320320D0 (de) |
| WO (1) | WO2005021530A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1497266T1 (sl) | 2002-03-27 | 2008-10-31 | Glaxo Group Ltd | Derivati kinolina in njihova uporaba kot ligandi 5-ht6 |
| EP1558582B1 (de) | 2003-07-22 | 2005-12-21 | Arena Pharmaceuticals, Inc. | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| GB0407025D0 (en) * | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
| GB0425548D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Radiolabelled ligands |
| WO2006062481A1 (en) * | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
| WO2007108744A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators |
| WO2007108743A2 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel quinazolines as 5-ht6 modulators ii |
| EP1999121A1 (de) * | 2006-03-17 | 2008-12-10 | AstraZeneca AB | Neue tetraline als 5-ht6-modulatoren |
| US20090203708A1 (en) * | 2006-07-05 | 2009-08-13 | Korea Research Institute Of Chemical Technology | Novel substituted-1-h-quinazoline-2,4-dione derivatives, preparation method thereof and pharmaceutical composition containing the same |
| EP2254564A1 (de) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| EP3166924B1 (de) | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatische heterocyclische derivate und pharmazeutische anwendungen davon |
| HK1245660A1 (zh) | 2015-06-12 | 2018-08-31 | Axovant Sciences Gmbh | 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| PH12021551324A1 (en) | 2019-01-08 | 2022-04-25 | Kyorin Seiyaku Kk | 15-pgdh inhibitor |
| US12304897B2 (en) | 2019-01-31 | 2025-05-20 | Kyorin Pharmaceutical Co., Ltd. | 15-PGDH inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| KR100889718B1 (ko) * | 2001-06-11 | 2009-03-23 | 바이오비트럼 에이비(피유비엘) | 치환 술폰아미드 화합물, cns 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법 |
| JP2005511625A (ja) * | 2001-11-14 | 2005-04-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 向精神薬としてのピラゾール誘導体 |
| SI1497266T1 (sl) * | 2002-03-27 | 2008-10-31 | Glaxo Group Ltd | Derivati kinolina in njihova uporaba kot ligandi 5-ht6 |
| WO2003080608A2 (en) * | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
-
2003
- 2003-08-29 GB GBGB0320320.5A patent/GB0320320D0/en not_active Ceased
-
2004
- 2004-08-26 WO PCT/EP2004/009724 patent/WO2005021530A1/en not_active Ceased
- 2004-08-26 AT AT04764687T patent/ATE418550T1/de not_active IP Right Cessation
- 2004-08-26 US US10/570,002 patent/US20080275040A1/en not_active Abandoned
- 2004-08-26 DE DE602004018658T patent/DE602004018658D1/de not_active Expired - Fee Related
- 2004-08-26 EP EP04764687A patent/EP1660483B1/de not_active Expired - Lifetime
- 2004-08-26 JP JP2006524347A patent/JP2007504114A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005021530A1 (en) | 2005-03-10 |
| GB0320320D0 (en) | 2003-10-01 |
| EP1660483A1 (de) | 2006-05-31 |
| JP2007504114A (ja) | 2007-03-01 |
| EP1660483B1 (de) | 2008-12-24 |
| DE602004018658D1 (de) | 2009-02-05 |
| US20080275040A1 (en) | 2008-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113306T1 (el) | Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6 | |
| DE602004018658D1 (de) | 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns-erkrankungen | |
| DE60309852D1 (de) | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden | |
| HRP20041005B1 (hr) | Kinolinski i izokinolinski derivati, postupci njihove proizvodnje, te naäśini njihove primjene kao sredstava za spreäśavanje (suzbijanje) upalnih procesa | |
| ATE384050T1 (de) | Benzazepinderivate als histamin-h3-antagonisten | |
| YU37904A (sh) | Benzimidazoli kao korisni inhibitori proteinske kinaze | |
| ATE320426T1 (de) | Harnstoffderivate und ihre verwendung | |
| ATE402165T1 (de) | Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten. | |
| ATE457313T1 (de) | Bicyclische heterocyclische p-38-kinase- inhibitoren | |
| EA200701252A1 (ru) | Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10 | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| TW200503710A (en) | Novel compounds | |
| DE602004007672D1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
| ATE433966T1 (de) | Methylendipiperidinderivate | |
| ATE347555T1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
| TW200514781A (en) | Novel compounds | |
| SG149045A1 (en) | Novel fused pyrrolocarbazoles | |
| MY149041A (en) | Novel fused pyrrolocarbazoles | |
| IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| UY26426A1 (es) | Nuevos compuestos | |
| MXPA05004273A (es) | Derivados de fenilalquil y piridilalquil piperazina. | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| BRPI0409958A (pt) | quinolinas de benzofuranil- e benzotienil-piperazinil quinolinas e métodos para o seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |